Press release
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, Consumer Demand and Key Opportunities
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies have fueled growth in the CIDP treatment market. With an expanding patient base, the increasing adoption of innovative biologics, and the rising demand for home-based infusion therapies, the market is poised for steady growth through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71900
Market Overview
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market was valued at USD 3.2 billion in 2024 and is projected to grow at a CAGR of 7.4% between 2024 and 2034, reaching approximately USD 6.6 billion by 2034.
Key Highlights
• Drivers: Rising prevalence of autoimmune disorders, increased adoption of intravenous immunoglobulin (IVIg) therapy, and advancements in plasma exchange and corticosteroid treatments.
• Challenges: High cost of immunoglobulin therapies, limited awareness in low-income regions, and the risk of relapse requiring lifelong management.
• Leading Players: CSL Behring, Grifols S.A., Octapharma AG, Takeda Pharmaceutical, Kedrion Biopharma, Pfizer Inc., Bayer AG, Sanofi, Biotest AG, and Baxter International.
Segmentation Analysis
By Product
• Intravenous Immunoglobulin (IVIg)
• Subcutaneous Immunoglobulin (SCIg)
• Corticosteroids
• Plasma Exchange (Plasmapheresis)
• Immunosuppressants
• Emerging Biologics & Monoclonal Antibodies
By Platform
• Hospital-Based Therapies
• Home-Based Infusion Therapies
By Technology
• Conventional Immunotherapy
• Advanced Immunoglobulin Delivery Systems
• Monoclonal Antibody Innovations
By End Use
• Hospitals
• Specialty Neurology Clinics
• Ambulatory Care Centers
• Homecare Settings
By Application
• Adult Patients
• Pediatric Patients
Segmentation Summary
Intravenous immunoglobulin (IVIg) therapy remains the gold standard for CIDP management, accounting for the majority of market revenue. However, subcutaneous immunoglobulin (SCIg) is rapidly gaining traction due to ease of administration and patient preference for homecare settings. Biologics and monoclonal antibodies under development promise to expand future treatment options.
Regional Analysis
North America
• Largest market share driven by advanced healthcare infrastructure, high diagnosis rates, and strong adoption of IVIg therapies.
• The U.S. dominates due to favorable reimbursement policies and growing clinical research activities.
Europe
• Strong demand supported by well-established rare disease management programs and wide availability of plasma therapies.
• Germany, France, and the U.K. lead with robust adoption of IVIg and SCIg treatments.
Asia-Pacific
• Fastest-growing region, fueled by rising awareness of rare diseases, increasing healthcare investments, and expanding access to advanced immunotherapies.
• China, Japan, and India are major growth contributors.
Middle East & Africa
• Gradual expansion due to increasing awareness and growing access to plasma therapies.
• Limited affordability and infrastructure remain barriers, though GCC countries are seeing improved uptake.
Latin America
• Brazil and Mexico are leading regional markets, with increased investment in neurology and rare disease care.
Regional Summary
North America and Europe dominate revenues today, but Asia-Pacific is projected to achieve the highest CAGR due to an expanding patient pool, rapid healthcare modernization, and improved diagnostic infrastructure.
Market Dynamics
Key Growth Drivers
• Increasing prevalence of autoimmune and neurological disorders globally.
• Growing adoption of IVIg and SCIg therapies.
• Rising healthcare spending on rare disease management.
• Expanding clinical trials pipeline for biologics and monoclonal antibodies.
Key Challenges
• High cost of immunoglobulin and biologic therapies.
• Relapse risks requiring ongoing and lifelong treatment.
• Limited awareness and underdiagnosis in emerging markets.
Latest Trends
• Expansion of home-based infusion therapies for patient convenience.
• Development of long-acting immunoglobulin formulations.
• Clinical trials for monoclonal antibodies and next-generation biologics targeting CIDP.
• Increased partnerships between plasma therapy companies and healthcare providers.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71900/cognitive-impairment-associated-with-schizophrenia-market
Competitor Analysis
Major Players
• CSL Behring - Market leader in immunoglobulin therapies for rare diseases.
• Grifols S.A. - Strong plasma therapy portfolio.
• Octapharma AG - Specialized in immunotherapy and neurology-focused products.
• Takeda Pharmaceutical - Wide portfolio in rare diseases and immunology.
• Kedrion Biopharma - Focused on plasma-derived therapies.
• Pfizer Inc. - Expanding into neurology and biologic treatments.
• Bayer AG - Active in R&D for autoimmune disease therapies.
• Sanofi - Strong pipeline of biologics for rare diseases.
• Biotest AG - Specialist in plasma proteins and immunotherapy.
• Baxter International - Innovator in infusion and plasma therapies.
Competitive Landscape Summary
The CIDP market is moderately consolidated, with plasma therapy giants dominating IVIg and SCIg treatments, while pharmaceutical leaders focus on biologics and R&D pipelines. Strategic alliances, product launches, and expansion into emerging markets are key strategies shaping competition.
Conclusion
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is poised for robust growth over the next decade. Rising prevalence, improved diagnostic capabilities, and the increasing adoption of IVIg and SCIg therapies are driving expansion. While high costs and limited awareness remain obstacles, advancements in biologics and home-based care create strong opportunities.
By 2034, the market is expected to reach USD 6.6 billion, underscoring steady demand for immunoglobulin therapies and novel treatment approaches. Companies focusing on innovation, affordability, and patient-centric delivery methods will be best positioned to capture market growth.
For stakeholders, the CIDP market represents a rare disease opportunity with significant potential to improve patient outcomes and expand access to life-changing therapies worldwide.
This report is also available in the following languages : Japanese (統合失調症に伴う認知障害市場), Korean (정신분열증과 관련된 인지 장애 시장), Chinese (精神分裂症相关认知障碍市场), French (Déficience cognitive associée à la schizophrénie), German (Markt für kognitive Beeinträchtigungen im Zusammenhang mit Schizophrenie), and Italian (Deficit cognitivo associato al mercato della schizofrenia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71900
Our More Reports:
Atypical Teratoid Rhabdoid Tumors Market
https://exactitudeconsultancy.com/reports/71926/atypical-teratoid-rhabdoid-tumors-market
Chronic Progressive Multiple Sclerosis Market
https://exactitudeconsultancy.com/reports/71928/chronic-progressive-multiple-sclerosis-market
Clinically Isolated Syndrome (CIS) Market
https://exactitudeconsultancy.com/reports/71930/clinically-isolated-syndrome-cis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4179642 • Views: …
More Releases from Exactitude Consultancy
Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at …
Introduction
Cell therapy has emerged as a transformative pillar of modern medicine, offering the potential to repair, replace, or regenerate damaged tissues and organs. From CAR-T cell therapies for oncology to stem cell therapies for regenerative medicine, the field is redefining treatment paradigms across oncology, neurology, cardiology, and rare diseases.
As clinical pipelines expand and more therapies achieve regulatory approval, demand for efficient and scalable cell therapy manufacturing has surged. Specialized technologies…
Despite safety concerns, adavosertib exhibits early antitumor activity in uterin …
Uterine serous carcinoma (USC) is a rare but highly aggressive subtype of endometrial cancer, accounting for less than 10% of endometrial cancer cases but contributing to a disproportionately high mortality rate. It is often diagnosed at advanced stages, making it difficult to treat with conventional methods.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873
In recent years, the treatment landscape has expanded beyond chemotherapy and surgery to include targeted therapies,…
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Imp …
Catheter-related bloodstream infections (CRBSIs) are among the most common and serious complications associated with intravascular catheters used in hospitals and long-term care settings. These infections can lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. With the rising use of central venous catheters, particularly among critically ill patients, oncology cases, and those requiring long-term intravenous therapy, the global demand for effective prevention and treatment solutions is growing…
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
Introduction
Antibody-drug conjugates (ADCs) represent one of the most innovative breakthroughs in oncology, combining the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By delivering highly toxic payloads directly to cancer cells, ADCs minimize systemic toxicity and enhance therapeutic efficacy.
As cancer incidence rises worldwide and the limitations of conventional chemotherapy become more evident, ADC technology is gaining momentum. With advancements in linker chemistry, payload design, and next-generation…
More Releases for CIDP
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Key Trend Reshaping the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) …
What combination of drivers is leading to accelerated growth in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. Rising healthcare expenditure is a result of increased investments in medical infrastructure, demand for advanced treatments, expanded insurance coverage, and efforts to improve healthcare access. This increased spending facilitates better diagnosis and management of CIDP, a…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Forayi …
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma…
